Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aurora-A hinders tumor-suppressor to allow chemotherapy resistance

28.02.2012
UT MD Anderson scientists find molecular path of protein associated with hard-to-treat cancers

A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.

"Overexpression of Aurora Kinase-A in tumors has been correlated with resistance to DNA-damaging chemotherapy, but we haven't known how this occurs," said senior author Subrata Sen, Ph.D., professor in The University of Texas MD Anderson Cancer Center Department of Molecular Pathology.

"Our discovery that Aurora A blocks the proper functioning of the tumor-suppressor p73 is a step toward understanding and addressing chemotherapy resistance with more effective treatment combinations," Sen said. Drugs that inhibit Aurora kinases are under development and some have advanced to cancer clinical trials.

Like p53, its better-known cousin, the tumor-suppressor p73 monitors DNA damage during cell division and orders apoptosis - programmed cell death - when it detects damage that can't be repaired. It's an ally of DNA-damaging chemotherapy such as cisplatin, which is designed to trigger apoptosis.

"The role of p73 in the maintenance of genomic stability has been better recognized in recent years and this tumor suppressor is believed to be functionally more important in cells that lack p53," Sen said. Inactivation of p53 is common in many types of solid tumors.

Sticking a phosphate group on p73 keeps it out of the nucleus

Having detected DNA damage, p73 works in the cell nucleus to activate genes that cause cell death.

Aurora-A is a kinase, a protein that regulates other proteins by attaching phosphate groups, consisting of one phosphorus atom connected to four oxygen atoms, at specific binding sites.

Sen and colleagues found that Aurora-A phosphorylates p73 at a specific site and when that happens:
p73 loses its ability to bind to DNA and to transactivate its target genes
p73 gets locked outside the nucleus in the cell's cytoplasm.
The researchers found lung cancer cells overexpressing Aurora-A have p73 evenly distributed in the nucleus and cytoplasm, but when treated with an Aurora-A inhibitor, p73 is found mainly in the nucleus. They repeated this experiment with similar results in breast and pancreatic cancer cell lines in which Aurora-A is overexpressed.

Mortalin ties phosphorylated p73 in cytoplasm

Sen and colleagues found that the protein mortalin binds to p73 that's been phosphorylated by Aurora-A, and plays a role moving p73 out to the cytoplasm and keeping it there. Mortalin has been implicated in tumor formation and immortalization.

In addition to DNA damage, p73 also regulates the mitotic spindle assembly checkpoint, which regulates a specific mechanism involved in the normal separation of chromosomes during cell division. The team found that Aurora-A phosphorylation of p73 also inactivates this checkpoint function.

They also found Aurora-A expressed at normal levels has a regular role to play in phosphorylating p73 in normal spindle assembly checkpoint function during cell division.

Aurora-A effect on p73 found in human pancreatic cancer

When they treated lung cancer cells with cisplatin, cells with phosphorylated p73 were least sensitive to cell death caused by the chemotherapy. In the absence of Aurora-A overexpression, cells were more sensitive to cisplatin treatment.

The team analyzed p73 and Aurora-A in 114 samples of human pancreatic ductal adenocarcinoma at MD Anderson and found 51 (44.7 percent) had high Aurora-A expression and 37 of those had high levels of p73 in the cytoplasm. Of the 63 low-Aurora-A tumors, only 18 (28.6 percent) had high levels of p73 in the cytoplasm.

Inactivation of the DNA and spindle damage-induced cell death pathways make these pancreatic tumors resistant to chemotherapy and radiation, the researchers noted. Further analysis of p73 phosphorylation tumor profiles and sensitivities to chemotherapy and radiation would assist in the development of targeted therapies and combinations.

Sen and colleagues, as well as other research teams, previously found that Aurora-A phosphorylation also inhibits p53-induced cell death after chemotherapy or radiation treatment. The new findings suggest both p53 and p73 DNA damage responses are blocked by Aurora-A phosphorylation after they interact with mortalin and are moved to the cytoplasm.

Co-authors with Sen are first author Hiroshi Katayama, Ph.D., Jin Wang, Warapen Treekitkarnmongkol, Ph.D., Kaori Sasai, Ph.D., Hui Zhang, Ph.D., Shoulei Jiang, Ph.D., Sandip Chakraborty, and Ralph Arlinghaus, Ph.D., of MD Anderson's Department of Molecular Pathology; Hidehiko Kawai, Ph.D., and Fumio Suzuki, Ph.D., of the Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan; Hua Wang, M.D., Ph.D., Jinsong Liu, M.D., Ph.D., and Huamin Wang, M.D., Ph.D., of MD Anderson's Department of Pathology; Henry Adams, of MD Anderson's Department of Genetics; James Mobley, Ph.D., and William Grizzle, M.D., of the University of Alabama at Birmingham Comprehensive Cancer Center.

This research was funded by grants from the National Cancer Institute, including the MD Anderson Cancer Center Support Grant, and an NCI Early Detection Research Network award.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For eight of the past 10 years, including 2011, MD Anderson has ranked No. 1 in cancer care in "Best Hospitals," a survey published annually in U.S. News & World Report.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht Antibiotic resistances spread faster than so far thought
18.02.2019 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht The Lypla1 Gene Impacts Obesity in a Sex-Specific Manner
18.02.2019 | Deutsches Zentrum für Diabetesforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Regensburg physicists watch electron transfer in a single molecule

For the first time, an international team of scientists based in Regensburg, Germany, has recorded the orbitals of single molecules in different charge states in a novel type of microscopy. The research findings are published under the title “Mapping orbital changes upon electron transfer with tunneling microscopy on insulators” in the prestigious journal “Nature”.

The building blocks of matter surrounding us are atoms and molecules. The properties of that matter, however, are often not set by these building blocks...

Im Focus: University of Konstanz gains new insights into the recent development of the human immune system

Scientists at the University of Konstanz identify fierce competition between the human immune system and bacterial pathogens

Cell biologists from the University of Konstanz shed light on a recent evolutionary process in the human immune system and publish their findings in the...

Im Focus: Transformation through Light

Laser physicists have taken snapshots of carbon molecules C₆₀ showing how they transform in intense infrared light

When carbon molecules C₆₀ are exposed to an intense infrared light, they change their ball-like structure to a more elongated version. This has now been...

Im Focus: Famous “sandpile model” shown to move like a traveling sand dune

Researchers at IST Austria find new property of important physical model. Results published in PNAS

The so-called Abelian sandpile model has been studied by scientists for more than 30 years to better understand a physical phenomenon called self-organized...

Im Focus: Cryo-force spectroscopy reveals the mechanical properties of DNA components

Physicists from the University of Basel have developed a new method to examine the elasticity and binding properties of DNA molecules on a surface at extremely low temperatures. With a combination of cryo-force spectroscopy and computer simulations, they were able to show that DNA molecules behave like a chain of small coil springs. The researchers reported their findings in Nature Communications.

DNA is not only a popular research topic because it contains the blueprint for life – it can also be used to produce tiny components for technical applications.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Global Legal Hackathon at HAW Hamburg

11.02.2019 | Event News

The world of quantum chemistry meets in Heidelberg

30.01.2019 | Event News

Our digital society in 2040

16.01.2019 | Event News

 
Latest News

The Internet of Things: TU Graz researchers increase the dependability of smart systems

18.02.2019 | Interdisciplinary Research

Laser Processes for Multi-Functional Composites

18.02.2019 | Process Engineering

Scientists Create New Map of Brain’s Immune System

18.02.2019 | Studies and Analyses

VideoLinks
Science & Research
Overview of more VideoLinks >>>